Clinical Trials Logo

Dermatitis, Contact clinical trials

View clinical trials related to Dermatitis, Contact.

Filter by:

NCT ID: NCT00640250 Completed - Contact Dermatitis Clinical Trials

Clinical Evaluation of T.R.U.E. TEST® Panel 3.2 Allergens: Dose Response

Start date: April 2008
Phase: Phase 2
Study type: Interventional

We propose a prospective, multi-center, double-blind, randomized study comparing the diagnostic performance (primary) and safety (secondary) of 3 concentrations of Disperse blue 106 and 4 concentrations of Bronopol in 40 adult subjects (20 subjects per allergen) with a clinical history of contact dermatitis and a positive patch test (current or previous) to the corresponding reference petrolatum allergen ("sensitives").

NCT ID: NCT00614289 Completed - Contact Dermatitis Clinical Trials

Novel Topical Treatment of Hand Dermatitis (Eczema)

Start date: August 2006
Phase: Phase 1
Study type: Interventional

This study is designed as a prospective, randomized, double-blind right/left comparison of Epikeia coatings to improve hand dermatitis.

NCT ID: NCT00612768 Completed - Dermatitis, Contact Clinical Trials

Clinical Evaluation of T.R.U.E. TEST® Fragrance Mix and Thimerosal Allergens:Bioequivalence of PVP Formulations

Start date: January 2008
Phase: Phase 2
Study type: Interventional

Open, prospective, multi-center study to evaluate the bioequivalence of povidone (PVP) formulations of 2 T.R.U.E. TEST allergens: fragrance mix and thimerosal.

NCT ID: NCT00555178 Completed - Psoriasis Clinical Trials

Regulatory T Cells (Tregs) in Polymorphic Light Eruption

Start date: March 2008
Phase: N/A
Study type: Observational

Polymorphic light eruption (PLE) is a photodermatosis with an extremely high prevalence, particularly among young women (up to 20%). The disease is characterized through itchy skin lesions on sun-exposed body sites occurring after sun exposure mostly in spring and early summer. Its etiopathogenesis is unknown but resistance to UV-induced immunosuppression with subsequent immune reactions against skin photoneoantigens has been suggested. Regulatory T cells (CD4+CD25+FoxP3+) (Tregs), a subset of T helper cells, are crucial for the induction of immunosuppression. We will test the hypothesis that PLE patients show pathogenic fluctuating Treg levels and function and related parameters over the seasons of the year, possibly being responsible for lack of immune modulation and autoimmunity in PLE. Natural or medical photohardening may normalize Treg deficiency in PLE and lead to clinical adaption in summer. Better insight into the pathogenesis of PLE may give clues to develop new therapeutic strategies.

NCT ID: NCT00549588 Completed - Clinical trials for Polymorphic Light Eruption

Sunscreen and After-sun-lotion Protection in Polymorphic Light Eruption

Start date: February 2004
Phase: N/A
Study type: Interventional

Polymorphic light eruption (PLE) is a common photodermatosis characterized by the appearance of itching, erythema, papules or vesicles on sun-exposed skin. Though etiology is unclear it is hypothesized that it is an abnormal immune response to autologous antigens generated by ultraviolet radiation (UVR). This randomized, double blinded left-right body side experimental comparison study was designed to assess the preventive effect of a sunscreen and topical DNA repair enzyme-containing after-sun lotion in PLE.

NCT ID: NCT00472901 Completed - Clinical trials for Polymorphic Light Eruption (PLE)

Phase III Trial of CUV1647 in Polymorphic Light Eruption (PLE)

Start date: May 2007
Phase: Phase 3
Study type: Observational

The purpose of this study is to determine whether the afamelanotide (CUV1647) formulation is effective in preventing PLE episodes or reducing the severity of PLE symptoms in patients with a well documented history of the disease. The study also aims to determine whether treatment with afamelanotide (CUV1647) can reduce the use of rescue medication in this group.

NCT ID: NCT00445029 Recruiting - Clinical trials for Allergic Contact Dermatitis

Pathophysiological Study of Allergic Contact Dermatitis to Para-Phenylenediamine (PPD). Analysis of Cellular and Molecular Targets in Skin Inflammation

Start date: March 2007
Phase: N/A
Study type: Observational

The current knowledge of the pathophysiology of allergic contact dermatitis is based on the murine model. In this model, CD8+ T cells are effector cells, and CD4+ T cells regulate the response by limiting the expansion of CD8+ T cells. The goal of this study is to characterize the pathophysiology of contact dermatitis, with patients allergic to para-phenylenediamine (PPD). We suppose that the CD8+ T cells are the effectors of the allergic contact dermatitis, although the regulator cells belong to the LT CD4+ population. We will test our hypothesis on blood samples, and cutaneous biopsies of patients allergic to PPD.

NCT ID: NCT00371163 Completed - Psoriasis Clinical Trials

Molecular and Cellular Characterization of Spongiotic Dermatitis

Spongiotic
Start date: September 2006
Phase: N/A
Study type: Observational

Spongiotic dermatitis is the histopathologic diagnosis commonly issued by dermatopathologists that encompasses atopic dermatitis, contact dermatitis, and other forms of eczematous dermatitis. The information obtained will assist in development of diagnostic methods for differentiation of the types of spongiotic dermatitis. This study also has the potential to lead to the dissection of pathologic pathways involved in these diseases and development of novel therapeutic agents.

NCT ID: NCT00311454 Not yet recruiting - Clinical trials for Allergic Contact Dermatitis Towards Quaternium-15

Quaternium-15, Use Test

Start date: April 2006
Phase: Phase 4
Study type: Interventional

The study is required by the FDA as part of a post-marketing commitment. The purpose of the study is to compare the reactivity of the TRUE Test quaternium-15 patch and a real use exposure.The subjects will wear the patch test for 48 hours and reading will be performed day 3 or 4. The use test will be applied from day 3 or 4 and untill reaction appears. Reactions from respectively TRUE Test and use test will be compared using the McNemar Change Test.

NCT ID: NCT00133341 Completed - Clinical trials for Allergic Contact Dermatitis

Clinical Evaluation of the 3 Allergens: Methyldibromoglutharonitrile, Parthenolide and Goldnatriumthiosulphate

Start date: April 2005
Phase: Phase 2
Study type: Interventional

It is the purpose of this study to determine the concentration of 3 allergens (goldnatriumthiosulphate, methyldibromoglutharonitrile [MDBGN], parthenolide) for diagnosing allergic contact dermatitis.